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Abstract
Although routinely collected electronic health records (EHRs) are widely used to examine outcomes
related to COPD, consensus regarding the identification of cases from electronic healthcare databases is
lacking. We systematically examine and summarise approaches from the recent literature.
MEDLINE via EBSCOhost was searched for COPD-related studies using EHRs published from January 1,
2018 to November 30, 2019. Data were extracted relating to the case definition of COPD and
determination of COPD severity and phenotypes.
From 185 eligible studies, we found widespread variation in the definitions used to identify people with
COPD in terms of code sets used (with 20 different code sets in use based on the ICD-10 classification
alone) and requirement of additional criteria (relating to age (n=139), medication (n=31), multiplicity of
events (n=21), spirometry (n=19) and smoking status (n=9)). Only seven studies used a case definition
which had been validated against a reference standard in the same dataset. Various proxies of disease
severity were used since spirometry results and patient-reported outcomes were not often available.
To enable the research community to draw reliable insights from EHRs and aid comparability between
studies, clear reporting and greater consistency of the definitions used to identify COPD and related
outcome measures is key.
Introduction
COPD is a common, chronic condition characterised by persistent respiratory symptoms and irreversible
expiratory airflow limitation, usually caused by chronic exposure to inhaled noxious substances. In clinical
practice, COPD can be diagnosed in patients suspected to have the condition by use of spirometry, which
also aids in the assessment of disease severity. Patients with COPD can also be grouped by their pattern of
exacerbations and symptom burden, and this phenotyping guides treatment decisions [1]. Guidelines
produced by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) divide patients into
“GOLD groups” based on these characteristics when delineating treatment strategies.
Research using routinely collected data from electronic health records (EHRs) and administrative databases
to study COPD has seen an upsurge in recent years, as the wealth of data accumulated as a by-product of
routine clinical care has made large, diverse populations accessible to researchers. However, this data has
not been generated for the purpose of research, and important information such as spirometry results and
patient-reported outcome measures are not often accessible in the data sources. Alternative measures are
thus frequently used to identify individuals with COPD, as well as determine disease severity and
phenotypes, though the extent to which the definitions used have been assessed for validity is unclear.
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Although the need to focus on the accuracy of case definitions has been emphasised [2], there is still
significant heterogeneity in the definitions used to identify common conditions in routinely collected data
[3–5]. In this systematic scoping review, we sought to summarise the range of methods used to identify
COPD, its severity and phenotypes in EHRs, and determine what proportion of case definitions in use
have been validated against reference standards.
Methods
We conducted a systematic scoping review [6] to answer our research questions: 1) how were individuals
with COPD identified in EHRs in the recent literature, 2) how many methods of case identification had
been validated against reference standards, 3) how were COPD severity and phenotypes defined and
4) what important data are missing from the data sources used in these studies?
Search strategy and eligibility criteria
A broad search strategy was developed to gather studies which used EHRs to identify individuals with
COPD (supplementary table S1). MEDLINE via EBSCOhost was searched January 15, 2020 for articles
published between January 1, 2018 and November 30, 2019. Our search was limited to those written in the
English language. There were no limitations as to study design.
EHRs included routinely collected, individual level data from administrative databases, disease registries,
electronic health records and any other electronic databases that were generated as a by-product of routine
healthcare. Studies using solely survey or trial data were excluded, along with studies not reporting original
data. We included studies identifying a study population of individuals with COPD or using COPD as a
primary outcome, but not those where COPD was just contained in a list of covariates.
Study selection and data extraction
Articles that did not fit the above eligibility criteria were excluded. Screening was initially conducted using
titles and abstracts, and full-texts were accessed when necessary. Information extracted from articles
deemed eligible for inclusion related to core study details, definitions of COPD diagnosis, severity and
phenotypes, and quality appraisal (supplementary table S2).
Article screening and data extraction were performed independently by two authors (S.S. and M.A.A.) for
20% of studies. S.S. then completed screening and extraction, with discussion with the wider study group
when necessary.
Results
Our search strategy identified 1226 articles for screening (supplementary table S1), of which 189 met our
eligibility criteria. We were able to access the full text for 185 of these, which are included in our review.
Most studies were conducted in North America, Taiwan and the UK (supplementary table S3). We
included studies with a range of designs, including retrospective cohort, self-controlled case series,
quasi-experimental, nested case–control, case crossover and descriptive/exploratory studies.
Identifying COPD
Studies often identified individuals with COPD using clinical codes. The most frequently used coding
scheme was the International Statistical Classification of Diseases and Related Health Problems (ICD) [7],
either alone or in conjunction with other coding schemes (supplementary table S4). However, studies using
the same coding scheme did not always use the same list of codes (“code set”) from within the scheme –
57 studies incorporating ICD-10-based codes used 20 different code sets to detect COPD (supplementary
table S5). Some studies did not report the specific code set used for case identification.
In order to achieve greater accuracy of case definitions, many studies used additional inclusion and
exclusion criteria in their definition of COPD. 139 (75%) used age as a criterion, with the lower age limit
varying from 18 to 66 (supplementary table S6). Some studies (21; 11%) required multiple COPD-related
event or claim codes. Some (25; 14%) gave more weight to inpatient care codes, requiring multiple
COPD-related codes if arising from primary care or outpatient care, but only one if arising from inpatient
care. 19 (10%) mandated presence of a spirometry code but results of spirometry were not always taken
into account. Nine (5%) specified ever-smoking as a criterion (supplementary table S7). A COPD-related
medication code was required by 31 out of 171 (18%) studies (not including studies whose aim was to
investigate COPD medications, since these would have automatically required presence of the medication).
The specific medication requirements and reporting of this varied by study, from requiring “the
prescription of at least one bronchodilator” [8] to mandating a greater frequency of medication use, with
“COPD medication use at least twice per year” [9] (where COPD medications were “long-acting
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muscarinic antagonist, long-acting beta-2 agonist (LABA), inhaled corticosteroid (ICS), ICS plus LABA,
short-active muscarinic antagonist (SAMA), short-acting beta-2 agonist (SABA), SAMA plus SABA,
methylxanthines, systemic corticosteroids and systemic beta agonists”) [9]. One study stated only that
patients were required to have been prescribed a “respiratory medication” but did not elaborate further [10].
With regard to exclusion criteria, 25 (14%) studies excluded those with a previous asthma diagnosis, some
excluded additional comorbid respiratory conditions and a few excluded individuals using specific
medications, such as leukotriene receptor antagonists which are mostly used in people with asthma.
COPD severity
Spirometry was utilised by 25 (14%) studies in their assessment of COPD severity, 8 (4%) as a binary
measure, 17 (11%) as an ordinal measure. Most studies did not assess disease severity in any form,
specifying that this was because they lacked the clinical data necessary. Proxies of severity were
sometimes used, ranging from chronic medication use (n=16; 9%) and measures relating to exacerbations
(n=16; 9%), to serum bicarbonate levels (n=1; 0.5%) [11], to algorithms purporting to represent
“complexity” (n=1; 0.5%) [12].
COPD phenotypes
Coexisting asthma was a phenotype examined by 15 (8%) studies and was generally identified by presence
of a previous asthma diagnosis code, but the specific code sets or identification methods were not always
reported. 12 (6%) studies compared those with high versus low blood eosinophil counts or concentrations,
although the thresholds used to determine high and low differed by study (supplementary table S8) [13–15].
Three studies performed sensitivity analyses to examine the effect of using differing thresholds [16–18].
Eight (4%) studies categorised individuals by their GOLD groups (i.e. taking into account both exacerbation
history and symptom burden), and 18 (10%) examined individuals by exacerbation history. Again, there was
variation in the code sets or algorithms used to identify an exacerbation, and the thresholds for high versus
low exacerbators.
Validation of case definitions
Eight (4%) studies in our review compared their definition of COPD against a reference standard and
provided sufficient information that a measure of validity could be calculated, although this may not have
been their primary purpose. Two of these studies identified themselves as “validation studies” and went on
to report measures of validity [19, 20].
Of the remaining 177 studies, a further 7 (4%) used a definition of COPD that had been previously
validated against a reference standard in the same database used for their research. Additional studies
referred to their case definition being “based on” validated definitions, but used code sets different to those
validated [21–23], or did not report the codes they used [18, 24, 25].
Some studies conducted analyses to justify the validity of their findings in different ways, such as
performing sensitivity analyses using different definitions of COPD [26].
Reporting
Only one study referred to the REporting of studies Conducted using Observational Routinely collected
Data (RECORD) guidance [27]. 15 (8%) studies stated that they used a particular coding scheme to
identify people with COPD but did not report the code set used. 107 (58%) studies did not report whether
they could access data related to (one of) smoking or spirometry. 44 (24%) reported that smoking
information was not available within their data source (supplementary table S7), and 60 (32%) reported
that spirometry events were unavailable.
Discussion
Principal findings
Electronic databases of routinely collected health data are used internationally to advance knowledge about
“real world” COPD by the research community. This systematic scoping review has demonstrated
significant variability in the methods used by researchers to identify individuals with COPD and describe
disease severity and phenotypes using routine data.
Only a limited number of studies used definitions that had been validated against reference standards in the
same database used for their study. Some studies referred to previous validation studies, but as they did not
report the code list they had used, it was not clear whether they used the same validated case definition.
The RECORD guidance [27] advocates for provision of a “complete list of codes and algorithms used to
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classify exposures, outcomes, confounders, and effect modifiers” in order to enhance research
transparency.
Interpretation and implications
Datasets generated as a by-product of routine clinical care are increasingly important and useful in
research, given the size, heterogeneity and unselected nature of the populations they provide access to.
However, there are pitfalls to their use, and among them is the use of case definitions with unknown
validity. Limitations in the reporting of code sets used by researchers further hinder comparability and
reproducibility.
For EHRs to provide meaningful insights, the case definitions used must be able to accurately detect
individuals with the condition in question. One way of ensuring this is to use definitions validated against
a reference standard. However, a definition validated in one database may not be transferable for use in
others. One validated definition for COPD in the UK’s Clinical Practice Research Datalink [28] specifies
being a current or ex-smoker as an inclusion criterion, given that COPD is uncommon in never-smokers in
the UK. However, in countries with a higher contribution of alternative risk factors to the development of
COPD [29], necessitating being an ever-smoker would likely reduce the sensitivity of this definition, as
will happen in all geographies where smoking prevalence is falling. Additionally, different research
questions may necessitate different case definitions – if investigators wanted to prioritise specificity over
sensitivity, a more restrictive definition would be used, and vice versa – but clarity in the rationale would
be useful to readers.
In addition to case definitions, the availability and accuracy of disease severity and phenotyping measures
is imperative for studies to be able to adequately adjust for potential confounding. However, many
administrative databases do not contain clinical detail at this level, so attempts at adjusting for severity in
analyses often use proxy measures, the choice of which may be determined by data availability and not be
validated against “true” disease severity. More often, no attempt at adjusting for disease severity is made,
leading to the potential of unmeasured confounding influencing results. Facilitating inclusion of clinically
important variables (such as common investigation results and patient-reported outcome measures) into
electronic health databases commonly used for research would be a useful and important intervention in
improving research outputs. Through the lens of COPD, inclusion of spirometry results and UK Medical
Research Council (MRC) dyspnoea scale scores would play a significant role in advancing research in the
field. Similarly, inclusion of echocardiogram results and New York Heart Association (NYHA) class
would likely be helpful for cardiovascular disease research. However, even when databases do hold such
information, there may be a high rate of missing data (e.g. 65% of patients in one study had no spirometry
recorded) [30]. This reflects real world patterns, and levels of missingness are likely to vary geographically
due to historic differences in clinical practice, or national incentive schemes.
Strengths and limitations
This is the first review, to our knowledge, to systematically examine methods of identifying individuals
with COPD in routinely collected EHRs. This approach has allowed us to objectively demonstrate the
variability in research practice in the field. We applied broad inclusion criteria ensuring representation
across the research field but confined our review to recent literature in order to ensure relevancy. We did
not include studies where COPD was only relevant due to being contained in a list of covariates (as is
often done, for example as part of the Charlson Comorbidity Index) [31], since an accurate case definition
for this purpose holds less importance. However, this means that our review does not fully encompass the
whole spectrum of the use of “COPD” in electronic health data research.
Conclusions
Although the interrogation of routinely collected EHRs is now commonplace in investigating important
research questions related to COPD, and provides huge value when used carefully, persistent limitations
constrain the quality of this research. The lack of clinically important variables in widely used databases
limits researchers’ ability to adjust for confounders such as disease severity. Variation in methods to
identify COPD and define outcome measures restricts comparability between studies. With the contribution
of EHRs to COPD research continuing to increase internationally, ensuring greater consistency of case
definitions and optimisation of reporting is key to enhancing the reliability of research outputs.
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